ACXP vs LGL Comparison

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

LGL Group Inc is a holding company engaged in services, merchant investment, and manufacturing business activities. The company has two reportable segments: Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications, including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.